Immunoprotection of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from Lactococcus garvieae against Lactococcosis in tilapia

Tsai, Ming‐An; Wang, Pei‐Chi; Cao, Thanh-Trung; Liao, Pei-Chih; Liaw, Li-Ling; Chen, Shih‐Chu

doi:10.2323/jgam.59.437

Cited by 23 publications

(19 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lactococcus garvieae infections in farmed tilapia became a problem in the industry during the last decade [8,18,19]. There are very few reports on studies of efficacious vaccines against this https://doi.org/10.1371/journal.pone.0230739.g002…”

Section: Discussionmentioning

confidence: 99%

A whole-cell Lactococcus garvieae autovaccine protects Nile tilapia against infection

et al. 2020

View full text Add to dashboard Cite

The autovaccine was produced in-house using a bacterial isolate from a diseased fish from the target farm. Three groups of 150 fish each were injected with either 1) an oil-adjuvanted, inactivated whole cell autovaccine, 2) adjuvant only or 3) PBS (negative control). Approximately 660 degree days post vaccination, the fish were challenged with 9x10 5 cfu bacteria/ fish by intraperitoneal injection and monitored for a further 28 days. Protection against infections was measured by lack of/reduced bacterial loads both by bacterial re-isolation and immunohistochemistry as well as absence of clinical signs/pathology. Significantly less L. garvieae (p<0.03) was re-isolated from either the adjuvant only or control groups compared to the vaccinated group. Furthermore, a significantly high amount (p<0.001) of anti-L. garvieae specific antibodies were observed in the vaccinated group compared to the adjuvant only or control groups at time of challenge. This coincided with protection against infection measured by absence/reduced L. garvieae re-isolation from internal organs, reduced clinical signs and lack of pathology in this group. In the adjuvant only and control groups, bacteria were re-isolated from the kidney, liver, spleen, brain and eyes during the first 14 days. The findings suggest that oil-based vaccines can protect tilapia against L. garvieae infection through an antibody mediated response.

show abstract

Section: Discussionmentioning

confidence: 99%

A whole-cell Lactococcus garvieae autovaccine protects Nile tilapia against infection

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, fish immunised with recombinant GAPDH alone showed a higher percentage cumulative mortality over a period of 14 d post-challenge than fish immunised with whole cells only and fish immunised with whole cells plus recombinant GAPDH. Tsai et al (2013) partially attributed this observation to the immunostimulatory effect of peptidoglycan in the whole-cell vaccine. The duration of protection af forded by the GAPDH vaccine in comparison with a whole-cell vaccine has not been investigated.…”

Section: Vaccinationmentioning

confidence: 97%

“…Despite promising results obtained with bacterial subunit vaccines in fish (Liu et al 2005, Ra et al 2009), reports on the development of subunit vaccines against lactococcosis are scarce. In a study by Tsai et al (2013), an antigen common to both KG+ and KG− L. garvieae sero types, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Shin et al 2009), was cloned and ex pressed in Escherichia coli BL21 (DE3). Western blotting analysis was used to show that both rabbit and tilapia antiserum reacted strongly with recombinant GAPDH.…”

Section: Vaccinationmentioning

confidence: 99%

Lactococcus garvieae: an emerging bacterial pathogen of fish

Meyburgh

Bragg²,

Boucher³

2017

Dis. Aquat. Org.

127

View full text Add to dashboard Cite

Lactococcus garvieae is the causative agent of lactococcosis, a hyperacute, haemorrhagic septicaemia of fish. This bacterium is also considered an emerging zoonotic pathogen, as reports of human infection are increasing. Significant economic loss in aquaculture is suffered as a result of lactococcosis, as numerous freshwater and marine species of commercial interest are affected. Development of antibiotic resistance in L. garvieae to several chemotherapeutic agents complicates and restricts treatment options. Effective, sustainable treatment and prevention options are thus needed, but progress is impeded by the lack of knowledge concerning several aspects of the disease and the pathogen. This review aims to present the latest research on L. garvieae, with specific focus on pathogenesis, virulence factors, risks associated with chemotherapeutic administration and possible control options.

show abstract

“…The formalin-inactivated whole-cell vaccine was prepared as in Tsai et al [21] with slight modifications. Following inactivation, the bacterial pellet was re-suspended at a final concentration of 10 10 CFU/mL in PBS containing 0.01% formalin.…”

Section: Bacterial Culture and Inactivation Of Bacteriamentioning

confidence: 99%

Efficacy of a formalin-inactivated vaccine against Streptococcus iniae infection in the farmed grouper Epinephelus coioides by intraperitoneal immunization

Huang

Chen

Wang

et al. 2014

Vaccine

Self Cite

View full text Add to dashboard Cite

Immunoprotection of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from Lactococcus garvieae against Lactococcosis in tilapia

Cited by 23 publications

References 47 publications

A whole-cell Lactococcus garvieae autovaccine protects Nile tilapia against infection

A whole-cell Lactococcus garvieae autovaccine protects Nile tilapia against infection

Lactococcus garvieae: an emerging bacterial pathogen of fish

Efficacy of a formalin-inactivated vaccine against Streptococcus iniae infection in the farmed grouper Epinephelus coioides by intraperitoneal immunization

Contact Info

Product

Resources

About